Ras Recombinant Rabbit Monoclonal Antibody [JE44-13] (HA721883)

UNIPROT #

P01111

PROTEIN NAME

Ras

SYNONYMS

C BAS/HAS antibody;C HA RAS1 antibody;C-BAS/HAS antibody;c-H-ras antibody;C-HA-RAS1 antibody;CTLO antibody;GTPase HRas antibody;GTPase KRas antibody;GTPase NRas antibody;H ras antibody;H RASIDX antibody;H-Ras-1 antibody;H-RASIDX antibody;Ha-Ras antibody;HAMSV antibody;HRAS antibody;HRAS1 antibody;K ras antibody;K RAS2A antibody;K RAS2B antibody;K RAS4A antibody;K RAS4B antibody;K-RAS antibody;KRAS antibody;KRAS1 antibody;KRAS2 antibody;N-RAS antibody;N-terminally processed antibody;NRAS antibody;NRAS1 antibody;p21ras antibody;RASH_HUMAN antibody;RASH1 antibody;RASK2 antibody;Transforming protein p21 antibody;v Ha ras Harvey rat sarcoma viral oncogene homolog antibody;v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody;v ras neuroblastoma RAS viral oncogene homolog antibody

SUBCELLULAR LOCATION

Cell membrane, Golgi apparatus membrane.

FUNCTION

Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS). CMEMS is a variant of Costello syndromDefects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC). Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.